Abstract
Background: Iron deprivation may be a therapeutic strategy for cancer. It can be achieved by using iron chelators. In this investigation, anti-neuroblastoma activities of a novel ferric chelator 2LL together with DFO, EDTA and DTPA were evaluated. Materials and Methods: SH-Sy5y cells were cultured at 37°C in 5% CO2/95% air in DMEM containing 10% fetal bovine serum. The cells were seeded in 96-well microtiter plates overnight. Then, chelating agents were added into the wells. After 48-hour incubation, viabilities were measured using the MTT method. Results: DTPA had an IC50 value between 60-100 μM; DFO produced about 40% inhibiting effect at 150 μM; 2LL and EDTA displayed about 10% inhibiting effect at high concentrations. Conclusion: For SH-Sy5y cells, DTPA showed the strongest inhibiting effect, DFO displayed a moderate inhibiting effect, while 2LL and EDTA produced minor inhibition. To develop iron chelators as powerful anti-cancer agents is still a challenging task.
Footnotes
- Received April 26, 2004.
- Accepted October 19, 2004.
- Copyright © 2005 International Institute of Anticancer Research (Dr. John G. Delinassios), All rights reserved